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Abstract 
 
Background Asthma is characterized by airway inflammation and bronchial hyperreactivity. It is 
conceived that aging may affect asthma characteristics, but this issue is still not completely clarified in 
clinical practice. 
Objective The present study investigated whether aging may affect some clinical and functional factors 
in outpatients with asthma visited in a real-world setting, such as clinical practice. 
Methods Globally, 391 outpatients (163 males, median age 47 years) with asthma were consecutively 
evaluated. The following parameters were assessed: history, including, smoking, comorbidity, and 
inhaled corticosteroids (ICS) use, physical examination, body mass index (BMI), lung function, level 
of asthma control, asthma control test (ACT), and fractional exhaled NO (FeNO). 
Results The elderly with asthma had: more frequently not controlled asthma, higher BMI, higher ICS 
dosages, more impaired lung function, including plethysmographic parameters, than adult asthmatics 
(p<0.001 for all, but p=0.002 for RV and p=0.008 for FRC). Elderly asthmatics were also less 
frequently allergic (p<0.001) and had less rhinitis comorbidity (p<0.001) and less nasal symptoms 
(p<0.05) than younger asthmatics. 
Conclusions The present study conducted in a real-world setting shows that aging significantly affects 
asthma, mainly concerning asthma control, lung function, and steroid-sensitivity. 
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Introduction 
 
Asthma is characterized by three main pathophysiological characteristics: airways inflammation, 
reversible bronchial obstruction, and bronchial hyper-reactivity (BHR) to different stimuli (1). It has 
been reported that rhinitis and obesity may be frequent comorbidities and can worsen asthma (2,3). 
Clinical and economic consequences of asthma can be significant in terms of: disability, significant 
costs, and death which is not rare (1,4). In particular, the elderly with asthma had the second highest 
rate of asthma-related hospitalizations and the highest number of asthma-related mortality (5). As the 
aging of the general population is a worldwide characteristic, asthma in old subjects represents an 
important challenge for the healthcare system.  
Generally speaking, lung function aging is a process that progresses throughout the entire life since the 
maturity (5,6). Decline of lung function is a para-physiologic event that may be further worsted by 
smoking, air pollution, inflammatory disorders, and other dysfunctions (5,7). In particular, raised 
stiffness of the chest wall, reduced lung elastic recoil, and respiratory muscles weakening characterize 
the lung aging (8). The aging-dependent decline in expiratory air flow is associated with progressive 
reduction of small airways calibre (9). Another aspect of aging lung is the risk of small airways 
collapsing during tidal breathing (10). Therefore, a more severe asthma in elderly patients has been 
advanced (11). Indeed, it has been identified a phenotype for older asthmatics having severe symptoms 
and impaired lung function (12,13,14). However, the above-mentioned studies did not investigate the 
different role of asthma duration and aging per se as specific pathogenic factors.  A recent study 
addressed this issue showing that age has a greater impact than asthma duration on risk of severe 
asthma, but the cut-off point was by 45 years (15). However, this study has already been conducted on 
a selected population of patients with severe asthma enrolled in the National Hearth Lung and Blood 
Institute severe asthma research program (SARP). On the basis of this background, we postulated the 
hypothesis that older asthmatics may show a worsening in clinical and functional outcomes than 
younger asthma patients. Therefore, the present study has the purpose of evaluating whether aging may 
have an impact on clinical and functional parameters in clinical practice, such as in outpatients with 
asthma observed in a real-life setting. 
Materials and Methods 
Patients  
This observational and cross-sectional study has included 391 consecutive Italian adult patients suffering 
from asthma. All these outpatients, included in the study, went to an asthma clinic (Asthma Clinic, San 
Luigi Hospital, Orbassano, Turin, Italy) for a specialist visit between January and December 2016. The visit 
included history, clinical examination, body mass index (BMI) measurement, spirometry, fractional exhaled 
nitric oxide (FeNO) measurement, asthma control test (ACT) questionnaire, and asthma control assessment 
according to the Global Initiative for Asthma (GINA) document (1). All these measurements were 
performed as routine follow-up.  
The study conformed to the local ethic criteria concerning the management of clinical data and written 
informed consent was obtained from each subject. 
Study Design and setting 
Asthma diagnosis was previously established and documented as well as rhinitis diagnosis and 
allergen-specific IgE positivity (i.e. sensitization). Inclusion criteria were adulthood (age >18 years) 
and documented asthma diagnosis, based on typical symptoms history consistent with reversibility to 
bronchodilators and/or bronchial hyper-responsiveness to methacholine (MCH) challenge. Exclusion 
criteria were history of lung disease other than asthma, coronary artery disease, congestive heart 
failure, or cor pulmonale, recent asthma exacerbation, presence of acute (in the last 4 weeks) or 
chronic upper and/or lower respiratory infections. Patients discontinued use of short acting and long 
acting bronchodilators, respectively for 4 and 12 hours before lung function measurement.  
Age, gender, smoking (current, past, or never), presence of comorbidity, including allergy, rhinitis, referred 
asthma and/or rhinitis symptoms in the last month, inhaled corticosteroids (ICS) mean dosages and use 
based on beclomethasone equivalence, presence of asthma signs, mainly wheezing, at physical examination, 
forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, forced 
expiratory flow at 25-75% of vital capacity (FEF25-75), residual volume (RV), total lung capacity (TLC,) 
RV/TLC ratio, functional residual capacity (FRC), FeNO, GINA asthma control level, ACT, were registered 
for all patients in the analysis.  
 
Functional assessment 
Forced expiratory volume in 1 second (FEV1) and forced (FVC) and slow (VC) vital capacities were 
measured according to Miller et al. (16). Lung volumes were measured according to American 
Thoracic Society (ATS)/European Respiratory Society (ERS) recommendations (17) using a body 
plethysmograph (Vmax Encore 62, Carefusion®, Hoechberg, Germany).  
Nitric oxide measurement  
FENO was measured with a chemoluminescence analyzer (Eco Medics CLD88 sp, Duernten, 
Switzerland), the detection limit of the apparatus was 1–5 parts per billion (ppb), as required by ATS 
guidelines, with a resolution of 1 ppb. The analyzer was calibrated daily, using a certified NO mixture. 
Exhaled NO was recorded with the single-breath method according to published guidelines (18). 
Subjects inhaled to total lung capacity from NO-free air and exhaled a single breath (without nose clip) 
through a mouthpiece at a mouth pressure of 45 cm water and at an expiratory flow of 50 mL/s. Mouth 
pressure was displayed on a computer screen in order to maintain a steady flow for the patients. The 
measurement was rejected if a stable flow was not maintained for at least 6 s of exhalation. Nitric 
oxide was measured at the plateau and expressed in ppb. 
Asthma control level 
Asthma control level was assessed according to the GINA guidelines and patients were classified as 
having: controlled, partly controlled or uncontrolled asthma (1). 
Asthma Control Test 
ACT questionnaire consisted of 5 questions with 5 possible answers, exploring the patient’s perception 
of his/her asthma control (19). The result could range between 0 and 25, where 25 was the optimal 
asthma control. 
Allergy 
Allergy was considered if there was a documented sensitization, assessed by skin prick test and/or 
measurement on serum, and the demonstration of a cause/effect relationship between exposure to 
sensitizing allergen and symptom occurrence. 
Rhinitis 
Rhinitis was considered if there was a history of typical nasal symptoms, such itching, sneezing, 
watery rhinorrhoea, and nasal obstruction. If the symptom occurrence was consistent with the exposure 
to sensitizing allergen the diagnosis of allergic rhinitis was made. 
Statistical analysis 
The patients were subdivided in 3 groups according to their age: 18-40 years (young adults), 41-64 
years (adults), and > 65 years (elderlies) as previously defined (20). The demographic and clinical 
features of the patients are expressed as mean ± standard deviation, median (25th – 75th percentiles, 
such as interquartile ranges-IQR), and frequencies (%). Chi square test was performed to determine 
any association between age class and clinical categorical variables. The strength of any significant 
relationship was indicated by the odds ratio (OR) with 95% confidence interval (CI).  One way 
ANOVA, or the non-parametric Kruskal Wallis test when appropriate, were performed to compare the 
continuous data between age classes. If necessary, a Bonferroni or a Conover-Inman post hoc tests 
were used for pairwise comparison. Test of Spearman was used for evaluating relationships between 
age (evaluated as continuous variable) and clinical and functional variables. A p <0.05 was considered 
statistically significant.  
Statistical analysis was computed using Statistical Package for Social Science (SPSS version 20, IBM, 
USA) and MedCalc v12.  
Results  
Table 1 shows the clinical and functional characteristics of the whole population. All individuals were 
Caucasians. The median age was 47.0 years (IQR: 35-61). Elderly asthmatics, such as aging more than 
65 years, were about 25% of the sample. Males were 41.7% and the mean BMI was 25.4. Most of 
patients were allergic (about 80%), most of them were poly-sensitized. Rhinitis comorbidity was very 
common: 89.8%. Referred symptoms for asthma and rhinitis were frequent: 65.5% and 75.2% 
respectively. The presence of asthma signs at clinical examination was 12.5%. Lung function values 
are reported in detail. Mean FeNO value was 30.92 ppb. ACT mean value was 20.17. About 40% of 
patients had good asthma control, whereas only 11.5% had uncontrolled asthma. About 90% of 
patients were treated with inhaled corticosteroids and the mean dosage of beclomethasone 
bioequivalence was 390 mcg/daily. In addition, 56.3% of patients never smoked, 35.8% were past 
smoker, and 8% were current smoker. Considering a possible association between smoking and the 
evaluated variables, there was no significant association except a trend for BMI and FeNO (p=0.053 
and 0.051 respectively). 
Comparison between age subgroups showed that for all clinical and functional variables analysed, but 
not for FeNO and TLC, there were statistical significant differences concerning older patients (Table 
2). In addition, all the asthmatics showed a lower frequency of allergy (Fig 1A), a higher frequency of 
partly controlled asthma (Fig 1B), a BMI higher than the other two groups (Fig 1C), and higher ICS 
dosages (Fig 1D). Lung function assessment revealed that there were significant differences 
concerning all parameters, but not for TLC (Table 2 and Fig 2). ICS dosages and measurements 
of lung function (in particular RV, RV/TLC, and FRC), progressively increased with increasing mean 
age of the patients, with statistically significant differences between the age groups (p<0.001). As 
regard to spirometric parameters such as FVC % of predicted, FEV1 % of predicted, FEV1/FVC, and 
FEF25-75 % of predicted, however, elderly asthmatics always showed significantly lower values 
compared to younger subjects. Statistically significant differences in FEV1/FVC and FEF25-75 % of 
predicted were observed also between old asthmatics and the other two groups. On the contrary, FeNO 
values and ACT scores did not differ among subgroups (Table 2).  
Adult asthmatics had three times more likely to have allergy than old asthmatics (OR: 3.14; IC 95%: 
1.76 – 5.59; p<0.001); and the probability, for young adult asthmatics of having allergy was eight 
times greater than old asthmatics (OR: 8.28; IC 95%: 3.98 – 17.23; p<0.001) as reported in Table 3. 
Similarly, rhinitis comorbidity and referred nasal symptoms were more likely in young adults and 
adults in comparison with elderly patients (Table 3). 
In addition, a statistically significant difference has been found between adult and old asthmatics who 
controlled asthma only partially or completely (Table 3). Finally, age was analysed as a continuous 
variable and relationships were calculated between age and clinical and functional variables. Findings 
are shown in Table 4. A strongly positive relationship was demonstrated between age and RV/TLC (r= 
0.77); moderately positive relationship between age and BMI (r= 0.43); moderately negative 
relationship between age and FEV1 (r= 0.43), FEV1/FVC (r= 0.5), FEF25-75 (r= 0.48). 
  
Discussion 
 
 
It is well known that lung function declines over time and aging is associated with increased chest 
stiffness, reduced elastic lung recoil, and weaker respiratory muscles. However, there is poor 
knowledge of aging impact on asthma in the daily clinical practice. The present real-world study 
demonstrated that the elderly with asthma had less frequently controlled asthma, higher BMI, higher 
ICS dosages, more impaired lung function, including plethysmographic parameters, than younger adult 
asthmatics as well as elderly asthmatics had less frequently allergy and rhinitis comorbidity and less 
referred nasal symptoms.  
In addition, there was a strongly positive relationship between age, as continuous variable, and 
RV/TLC as a consequence of aging of lung function. Moreover, there was a moderately positive 
relationship between age and BMI as expected: in fact, it is well known that adiposity increases over 
time. On the contrary, there were moderately negative relationships between age and FEV1, 
FEV1/FVC, and FEF25-75 so confirming the impact of age on bronchial obstruction as demonstrated by 
other analysis. Instead, smoking did not significantly affect the considered variables. 
These findings are basically consistent with some previous reports on asthma in the elderly (11-15) 
which showed the more severe asthma during aging. However, our study investigated the grade of 
asthma control and included plethysmography in a real-life setting, i.e. outpatient clinic. So, the 
outcomes are more representative of the daily clinical practice as the large trials are usually based on 
selected patients populations that cannot fully reflect the real asthma patients characteristics. 
The present study highlighted the concept that older asthmatics have more rarely well controlled 
asthma. This fact might depend on different factors, including impaired lung function, adiposity, non-
eosinophilic bronchial inflammation, and consequently steroidal resistance. 
In particular, the current findings clearly showed, and confirmed, worsening of lung function, mainly 
concerning FEV1, FVC, and RV. Thus, aging in asthma might mean greater limitation of air flows and 
air trapping (RV) probably because of diminished elastic recoil. This fact might be associated with a 
predominant neutrophilic bronchial inflammation as recently reported (21). This hypothesis is 
indirectly confirmed in our patients by lower FeNO values and lower allergy prevalence. This issue 
might be associated with the reported steroidal resistance. In this regard, the present study showed that 
older asthmatics use higher ICS dosages. This outcome could depend on different pathways. First, 
immune system is characterized by a diminished function as a consequence of imbalance of cellular 
pattern and cytokine profile (22). The elderly usually shows reduced lymphocytes and increased 
neutrophils (22,23). FeNO, a surrogate biomarker for type2 airway inflammation, trend to diminish in 
elderly asthmatics (23,24). Consistently, atopy inversely correlates with age and it could be speculated 
that airway neutrophilia may be sustained by a type1 and type3 immune response (25,26). In 
particular, Th17 polarization could identify asthmatics with a peculiar phenotype: the frequent 
exacerbators as recently reported (27). In addition, aging is characterized by a cytokine profile 
characterized by predominance of IL-1, IL-6, and TNF-: pro-inflammatory cytokines. This pattern 
maintains a chronic low-grade inflammation: the so called “inflammaging” (24). 
Another pathogenic factor may be adiposity. In fact, it is well known that there is a close link between 
asthma and obesity (28,29). Very recently, it has been reported that obese (and overweight) asthmatics 
have more impaired lung function than normo-weight ones (30). 
On the other hand, the outcomes of the current study are partially conflicting with a previous study that 
reported a strong association with rhinitis in elderly asthmatics (31). However, that study was 
conducted only on aged subjects. Another Italian study reported inconsistent data about the rate of 
uncontrolled asthma in elderly patients: on 350 patients about 1/3 had uncontrolled asthma, but also 
this study had no control groups (32). A Polish study reported very high rate of elderly asthmatics with 
uncontrolled asthma, but the authors did not demonstrate an association with comorbidities, and in 
addition observed that concomitant medications can significantly affect asthma control (33). 
Recent reviews on the evaluation and management of asthma in the elderly pointed out some relevant 
peculiarities: particularly functional and immunological changes associated with aging significantly 
affect the presentation of asthma (34-37). 
Moreover, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens 
(TENOR) study demonstrated that older (>65 years) asthmatics had significantly lower lung function, 
less nasal and ocular symptoms, lower health care use, greater use of ICSs, and fewer asthma control 
than younger asthmatics (38). Accordingly, the TENOR study further showed that very poorly 
controlled asthma was strongly predictive of future asthma exacerbations (38). A more recent TENOR 
updating reinforced these concepts underlying the importance of the difference in management 
between allergists and pulmonologists, mainly concerning older subjects (39).  
The present study has some relevant limitation: it was cross-sectional, no biomarkers were measured, 
asthma duration, cognitive function, frailty, recent exacerbations, and adherence to treatment were not 
considered, and  the number of patients was relatively limited. In particular, cognitive function, other 
comorbidities, and general frailty may significantly affect an adequate medication consumption as well 
as inhaler technique that may impair compliance and adherence to treatments (40,41). These issues 
deserve careful attention in the management of elderly asthmatics, as it is necessary more time to 
explain medication use and asthma education in elderly people than younger. All these aspects may 
significantly and negatively influence the control of asthma in elderly asthmatics. Moreover, the 
current study was conducted in a specific group of subjects, i.e. outpatients visited at an Asthma 
Clinic, therefore the outcomes could not be generalized, so further studies should be performed to 
answer to these unmet questions. 
On the basis of these concepts, it is conceivable that asthma in the elderly has various characteristics, 
including common comorbidities, cognitive impairment, reduced immune response, chronic low-grade 
inflammation, steroid-resistance, polypharmacy which could affect the control of asthma and lung 
function. Recently, it has been thereby proposed that ageing could also define a distinct asthma 
phenotype with impact on diagnosis and management (36). Therefore, there is the need to use a 
multidisciplinary approach able to consider in holistic fashion physical aspects, including assessment 
of lung function, airway inflammation, comorbidity, current polypharmacy, cognitive function, social-
economic situation, and psychological issues. In this regard, it has been recently reported that anxiety 
and depression may affect asthma control, even though age minimally affects this aspect in that cohort 
(42). Another relevant point, raised by TENOR study, is that elderly asthmatics perceive a poor 
communication with physicians. So, in managing elderly patients with asthma there is the need to 
adequately consider a good communication between patient and doctor, provide a clear action plan, 
including appropriate use of ICSs, correct inhaler technique, use of objective measure of asthma 
control, and adherence to prescribed medication regimens. In other words, to spend time for educating 
old asthmatics.  
In conclusion, the present study conducted in a clinical practice scenario shows that the elderly with 
asthma have rarely controlled asthma, more frequently impaired lung function, higher BMI, higher ICS 
dosages, and less frequently nasal problems than adult asthmatics. 
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Figures legends 
 
Figure 1: A=frequency of presence or absence of allergy; B= frequency of well controlled, 
partly controlled, and uncontrolled asthma; C= median, IQR, and SD of BMI; D= median, 
IQR, SD of ICS-dosages. All parameters are evaluated in the 3 sub-groups of age. 
 
Figure 2: A= median, IQR, and SD of FVC expressed as % of predicted; B= median, IQR, 
and SD of FEV1 expressed as % of predicted; C= median, IQR, and SD of FEV1/FVC; D= 
median, IQR, and SD of FEF25-75 expressed as % of predicted. All parameters are evaluated in 
the 3 sub-groups of age. 
 
  
Age (yrs) 
47.32±16.31 
47.00 [35.00 – 61.00] 
Age classes 
18-40 142 (36.3) 
41-64 149 (38.1) 
65-85 100 (25.6) 
Males, n (%) 163 (41.7) 
BMI 
25.43±4.98 
25.00 [22.00 -28.00] 
Allergy, n (%) 312 (79.8) 
Polysensitization, n (%) 228/312 (73.1) 
Rhinitis comorbidity, n (%) 351 (89.8) 
Asthma symptoms, n (%) 256 (65.5) 
Rhinitis symptoms, n (%) 294 (75.2) 
Asthma signs, n (%) 49 (12.5) 
FVC % of predicted 
100.06±18.19 
100 [89.00 – 110.00] 
FEV1 % of predicted 
88.56±20.91 
90.50 [77.35 – 102.50] 
FEV1/FVC 
74.79±13.13 
83.00 [77.00 – 90.00] 
FEF25-75 % of predicted 
63.75±30.73 
63.00 [40.60 – 87.00] 
RV % of predicted  133.16±42.76 
126.00 [101.00 – 155.50] 
TLC % of predicted  110.82±18.49 
109.00 [102.00 -120.00] 
RV/TLC  43.11±13.01 
42.00 [34.00 – 53.00] 
FRC % of predicted  117.53±31.16 
110.00 [96.75 – 137.00] 
FeNO (ppb) 
30.92±25.13 
22.00 [13.50 – 40.00] 
Asthma Control Test (ACT) 
20.17±4.34 
21.00 [17.00 – 24.00] 
Control of the asthma, n (%) 
Not controlled 11.5% 
Partly controlled                   45.5% 
Controlled                    41.2% 
ICS dosages (mcg) 
(N=186) 
390.32±311.50 
250.00 [200.00 – 500.00] 
ICS use None 10.2% 
Low dose 62.9% 
High dose 26.9% 
 
 
Table 1. Demographic and clinical characteristics (N = 391). Values are expressed as mean ± standard deviation, median (25th 
– 75th), frequency (%). BMI (Body Mass Index); ICS (Inhaled CoricoSteroids); for lung function variables see the text. 
 
 Age: 18-40 yrs Age: 41-64 yrs Age: 65-85 yrs p value Post hoc analysis 
BMI 22.10 (20.00 – 25.00) 24.86 (22.13 – 27.91) 27.00 (25.00 – 30.00) <0.001* 
<0.001 (18-40 vs 41-60) 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
FVC % of 
predicted 
100.88±14.69 103.75±17.40 93.32±21.81 <0.001* 
0.004 (18-40 vs 65-85)  
<0.001 (41-64vs 65-85) 
FEV1 % of 
predicted 
95.00 (86.00 - 105.00) 92.50 (80.00 - 103.00) 78.00 (54.00 - 99.00) <0.001* 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
FEV1/FVC 80.91±11.36 74.32±10.85 66.84±14.23 <0.001* 
<0.001 (18-40 vs 41-60) 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
FEF25-75 % of 
predicted 
77.50 (57.00 - 96.00) 63.00 (44.00 - 87.00) 36.70 (19.00 - 57.00) <0.001* 
<0.001 (18-40 vs 41-60) 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
FeNO 26.00 (15.40 - 45.00) 21.75 (13.50 -  40.00) 19.75 (12.80 - 34.00) 0.146  
Asthma Control 
Test (ACT) 
21.00 (18.00 - 24.00) 22.00 (17.00 - 24.50) 20.00 (16.00 - 22.50) 0.051  
ICS dosages 
(mcg) 
200.00 (0.00 - 250.00) 250.00 (200.00 - 400.00) 400.00 (250.00 - 600.00) <0.001* 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
RV 100.50 (87.50 - 138.00) 125.00 (102.50 - 148.50) 141.00 (116.00 - 165.00 ) 0.002* <0.001 (18-40vs 65-85) 
RV/TLC 30.12±8.62 38.75±10.28 53.57±8.51 <0.001* 
<0.001 (18-40 vs 41-60) 
<0.001 (18-40vs 65-85) 
<0.001 (41-64vs 65-85) 
FRC 107.50 (92.00 - 117.00) 105.00 (92.00 - 133.00) 124.50 (104.50 -145.00) 0.008* 
0.009 (18-40vs 65-85) 
0.009 (41-64vs 65-85) 
TLC 107.00 (101.00 -115.50) 110.00 (104.00 - 117.00) 112.00 (102.00 - 125.00) 0.437  
 
Table 2. Differences in clinical variables between age class of patients. Values are expressed as mean ± standard deviation or median (25th – 75th). BMI (Body Mass Index); ICS (Inhaled CoricoSteroids); 
for lung function variables see the text. 
  
  
 Age: 18-40 yrs Age: 41-64 yrs Age: 65-85 yrs p value 
Allergy 
No 11 (7.7) 27 (18.1) 41 (41.0) 
<0.001* Yes 131 (92.3) 122 (81.9) 59 (59.0) 
 OR [95%IC], p value 8.28 [3.98 – 17.23], <0.001* 3.14 [1.76 – 5.59], <0.001* Ref. 
Rhinitis comorbidity 
No 6 (4.2) 11 (7.4) 23 (23.0) 
<0.001* Yes 136 (95.8) 138 (92.6) 77 (77.0) 
 OR [95%IC], p value 6.77 [2.64 – 17.35], 0.001* 3.75 [1.73 – 8.10], 0.001* Ref. 
Rhinitis symptoms 
No 27 (19.0) 36 (24.3) 33 (33.0) 
0.045* Yes 115 (81.0) 112 (75.7) 67 (67.0) 
 OR [95%IC], p value 2.10 [1.16 – 3.79], 0.014* 1.53 [0.87 – 2.69], 0.136 Ref. 
Asthma signs 
No 121 (86.4) 133 (89.9) 85 (85.0) 
0.48 
Yes 19 (13.6) 15 (10.1) 15 (15.0) 
Asthma symptoms 
No 40 (28.2) 54 (36.5) 40 (40.0) 
0.13 
Yes 102 (71.8) 94 (63.5) 60 (60.0) 
Control of the asthma, n (%) 
Not controlled 15 (10.9) 21 (14.2) 9 (9.1) 
0.001* 
Partly controlled 56 (40.9) 58 (39.2) 64 (64.6) 
OR [95%IC], p value 0.53 [0.21 – 1.29], 0.16 0.39 [0.17 – 0.92], 0.031* Ref. 
Controlled  66 (48.2) 69 (46.6) 26 (26.3) 
 OR [95%IC], p value 1.52 [0.59 – 3.91], 0.38 1.14 [0.46 – 2.80], 0.78   
 
Table 3. Relationship  between age class of patients and clinical variables. Values are expressed as frequencies (percentage) 
 
  
 Age (years)  Correlation grade 
FVC Rho of Spearman -0.136** Very weakly negative 
p value 0.008  
N 385  
FEV1 Rho of  Spearman -0.285** Weakly negative 
p value 0.000  
N 385  
FEV1/FVC Rho of Spearman -0.499** Moderaelye negative 
p value 0.000  
N 385  
FEF25-75 Rho of Spearman -0.477** Moderately negative 
p value 0.000  
N 349  
FeNO Rho of Spearman -0.095 No correlation 
p value 0.075  
N 351  
BMI Rho of Spearman 0.428** Moderately positive 
p value 0.000  
N 279  
RV/TLC Rho of Spearman 0.766** Strongly  positive 
p value 0.000  
N 139  
 
 
Table 4. Relationship between age (evaluated as continuous variable) and clinical variables. 
